Merck & Co., Inc. (MRK) News Today

Skandinaviska Enskilda Banken AB publ lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 4.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,429,584 shares of the company'

Merck & Co., Inc. (NYSE:MRK) Shares Down 0.9%

MQS Management LLC acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,895 shares of the company's sto

Merck & Co., Inc. (NYSE:MRK) Shares Up 0.5%

Blair William & Co. IL raised its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 35.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 998,771 shares of the company's stock after acqui

L & S Advisors Inc decreased its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 33.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,912 shares of the company's stock after selling 21,

Merck & Co., Inc. (NYSE:MRK) Stock Price Up 1.6%

Cantor Fitzgerald restated an "overweight" rating and set a $155.00 price target on shares of Merck & Co., Inc. in a research report on Monday.

Moderna Inc. (NASDAQ: MRNA) made headlines during the pandemic for its messenger ribonucleic acid (mRNA) technology used in its COVID-19 vaccine Spikevax.

Citizens Financial Group Inc. RI grew its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 15.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 236,228 shares of the company's stock after acquirin

Keene & Associates Inc. lowered its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 21.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,185 shares of the company's stoc

Shares of Merck & Co., Inc. (NYSE:MRK - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fifteen brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a

Quilter Plc lifted its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 4.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 910,643 shares of the company's stock after acquiring an additi

J.W. Cole Advisors Inc. grew its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 10.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 57,761 shares of the company's stock after buying an additiona

Markets were mostly positive this week as benign inflation numbers did nothing to dampen expectations that the Federal Reserve will cut interest rates

Merck & Co., Inc. (NYSE:MRK) Shares Up 1.1%

Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant?

CoreCap Advisors LLC acquired a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 19,721 shares of the company's stock, valued at approximately $2,442,000. A number of other institutio

Summit Therapeutics has surged almost 100% this week, driven by positive Phase III trial results for its cancer therapy Ivonescimab.

Eagle Strategies LLC increased its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 149.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,883 shares of the company's stock after acquiring an additional 10,107 sh

Bahl & Gaynor Inc. grew its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 1.7% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 4,262,313 shares of the company's stock after acquiring an additional 71,019 shares during the period. Merck & Co.,

Headlands Technologies LLC acquired a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 41,919 shares of the company's stock, value

Merck & Co., Inc. (NYSE:MRK) Shares Gap Down to $117.84

LGT Group Foundation increased its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 1.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 697,137 shares of the company's stock a

LSV Asset Management lessened its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 9.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,356,770 shares of the company's stock after selling 631,010 shares during the period.

Kerusso Capital Management LLC acquired a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 23,634 shares of the company's stock, val

Letko Brosseau & Associates Inc. cut its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 9.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 234,239 shares of the company's stock a

Fluent Financial LLC increased its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 218.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,598 shares of the co

Wall Street analysts see big potential upside for small-cap biopharma firm Trevi Therapeutics. So, what does the firm do and how does it stand out?